Skip to main content
Article thumbnail
Location of Repository

Risk management of biosimilars in oncology: each medicine is a work in progress

By Arnold G. Vulto and Stacy A. Crow


Drug licensing and drug safety monitoring for standard chemical entities have been established and are routinely used. These have resulted in a solid foundation of knowledge from which confident therapeutic decisions can be made. For many chemical entities, this advanced level of experience is also present for the generic products. The expertise surrounding the development of biosimilar competitor versions is increasing and progress is encouraging. To address the re-engineering and comparability complexities of biosimilars, the European Union imposed a requirement that risk management plans be included in the medications’ marketing applications. This paper summarizes and discusses the circumstances complicating the public’s view of drug safety, historical incidents during the transition from innovative to competitor products, as well as retrospective assessments of the development and post-marketing experiences thus far with two biosimilars. Through assessing the market entries and post-marketing experiences of biosimilars used in oncology, the healthcare field can better prepare for the next wave of comparator-products: biosimilar monoclonal antibodies

Topics: Review
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2010). A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf
  2. (2010). Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf
  3. (2005). CHMP (Committee for Medicinal Products for Human Use)
  4. (2010). CHMP (Committee for Medicinal Products for Human Use) (2010a) Draft guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use.
  5. (2011). Cipriani A
  6. (2009). Concerns about erythropoiesis stimulating agents in oncology: an update.
  7. Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer associated anemia.
  8. (2009). Erythropoiesis stimulating agents in cancer patients: ESMO recommendations for use.
  9. (2009). Erythropoietin in cancer patients.
  10. (2005). Essay: the political logic of regulatory error.
  11. (2009). Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval.
  12. (2007). Governmental influences on drug development: striking a better balance.
  13. (1998). Limitations and strengths of spontaneous reports data. Clin Ther 20(Suppl C):C40–4
  14. (2008). Monoclonal antibodies—Regulatory challenges.
  15. (2008). Observational research, randomised trials, and two views of medical science.
  16. (2011). Opening up data at the European Medicines Agency.
  17. (2006). Protein therapeutics and their immunogenicity.
  18. (2009). Risk management of ESAs in cancer patients: a role for the hospital pharmacist.
  19. (2010). Risk management plans: are they a tool for improving drug safety?
  20. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
  21. (2008). Safety related regulatory actions for biologicals approved in the United States and the European Union.
  22. (2008). Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications. Oncologist 13(Suppl 3):4–10,
  23. (2008). Toward biosimilar monoclonal antibodies.
  24. (2008). Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
  25. (2010). Withdrawal of sibutramine leaves European doctors with just one obesity drug.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.